Related references
Note: Only part of the references are listed.KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer
Jianming Xu et al.
EUROPEAN JOURNAL OF CANCER (2023)
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Jian Zhang et al.
CLINICAL CANCER RESEARCH (2022)
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lauren M. Lucas et al.
PHARMACOLOGICAL REVIEWS (2022)
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Alison M. Schram et al.
CANCER DISCOVERY (2022)
Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer
Alexander Rau et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam et al.
LANCET ONCOLOGY (2022)
Avidity in antibody effector functions and biotherapeutic drug design
Simone C. Oostindie et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
Ilaria Marrocco et al.
EMBO MOLECULAR MEDICINE (2021)
An R package for generic modular response analysis and its application to estrogen and retinoic acid receptor crosstalk
Gabriel Jimenez-Dominguez et al.
SCIENTIFIC REPORTS (2021)
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures
Christel Larbouret et al.
CANCERS (2021)
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
Emilia Rabia et al.
MABS (2021)
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
Alexander Rau et al.
MABS (2021)
Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3
Alexander Rau et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI-B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
Junsheng Xue et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy
Shuyu Huang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
Donatella Romaniello et al.
CANCERS (2020)
Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells
Or-Yam Revach et al.
CANCER RESEARCH (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Cecile A. W. Geuijen et al.
CANCER CELL (2018)
A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways
Donatella Romaniello et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer
Andrew G. Hill et al.
CLINICAL CANCER RESEARCH (2018)
Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies
Joerg U. Schmohl et al.
TOXINS (2018)
Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent
Charlotte E. S. Hoogstins et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Babak Nami et al.
CANCERS (2018)
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors
Maicol Mancini et al.
EMBO MOLECULAR MEDICINE (2018)
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+Breast Cancers With ERBB Ligand Overexpression
Luis J. Schwarz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets
Shiyong Gong et al.
MABS (2017)
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Christophe Le Clorennec et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Structural basis of a novel heterodimeric Fc for bispecific antibody production
Hudie Wei et al.
ONCOTARGET (2017)
ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells
Arjan Kol et al.
ONCOTARGET (2017)
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
Yariv Mazor et al.
SCIENTIFIC REPORTS (2017)
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+Breast Cancers With ERBB Ligand Overexpression
Luis J. Schwarz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl et al.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2017)
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Zuguang Gu et al.
BIOINFORMATICS (2016)
A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets
John J. Rhoden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies
Josee Golay et al.
JOURNAL OF IMMUNOLOGY (2016)
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Songmao Zheng et al.
MABS (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Helle J. Jacobsen et al.
CLINICAL CANCER RESEARCH (2015)
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody
Stephen W. Jarantow et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Insights into the molecular basis of a bispecific antibody's target selectivity
Yariv Mazor et al.
MABS (2015)
Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
Mikkel W. Pedersen et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Examination of HER3 targeting in cancer using monoclonal antibodies
Nadege Gaborit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the THERAPY phase 1-2 trial
Eric Assenat et al.
ONCOTARGET (2015)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk
Shi Hu et al.
CANCER RESEARCH (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
Consequences of feedback in signal transduction for targeted therapies
Bertram Klinger et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
AXL Mediates Resistance to Cetuximab Therapy
Toni M. Brand et al.
CANCER RESEARCH (2014)
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Mari Iida et al.
MOLECULAR CANCER (2014)
MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Jonathan B. Fitzgerald et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Identification of Anti-ErbB2 Dual Variable Domain Immunoglobulin (DVD-Ig™) Proteins with Unique Activities
Jinming Gu et al.
PLOS ONE (2014)
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
Gaeelle Thomas et al.
ONCOTARGET (2014)
Network quantification of EGFR signaling unveils potential for targeted combination therapy
Bertram Klinger et al.
MOLECULAR SYSTEMS BIOLOGY (2013)
The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential
Beatrice Clemenceau et al.
MABS (2013)
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
Daniela A. Ferraro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Ruth Maron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
Daniel C. Kirouac et al.
SCIENCE SIGNALING (2013)
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
Shuiliang Wang et al.
BREAST CANCER RESEARCH (2013)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
Christel Larbouret et al.
NEOPLASIA (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
Timothy R. Wilson et al.
CANCER CELL (2011)
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
Gabriele Schaefer et al.
CANCER CELL (2011)
Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers A NEW METHOD TO EVALUATE THE EFFICIENCY OF TARGETED THERAPY USING MONOCLONAL ANTIBODIES
Nadege Gaborit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
Raphaela Fritsche-Guenther et al.
MOLECULAR SYSTEMS BIOLOGY (2011)
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
C. Larbouret et al.
ANNALS OF ONCOLOGY (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
Jamie B. Spangler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Frederic Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data
William W. Chen et al.
MOLECULAR SYSTEMS BIOLOGY (2009)
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
Tsipi Ben-Kasus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
M. K. Robinson et al.
BRITISH JOURNAL OF CANCER (2008)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
Christel Larbouret et al.
CLINICAL CANCER RESEARCH (2007)
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines
Jun Kurai et al.
CLINICAL CANCER RESEARCH (2007)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy
LM Friedman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors
B Schoeberl et al.
NATURE BIOTECHNOLOGY (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
